-transparent.png){kind=logo}
Progabide, a specific and clinically used GABA receptor agonist, was tested for its ability to suppress ethanol withdrawal syndrome. Male rats were rendered physically dependent on ethanol by feeding for 12 days on a liquid diet in which ethanol isocalorically replaced dextrose. Progabide (100-400 mg/kg i.p.), administered 8 h after ethanol was withdrawn, produced a dose-related inhibition of both tremors and audiogenically induced seizures. A single dose of 400 mg/kg of progabide completely suppressed all ethanol withdrawal reactions. Seizures were more sensitive to the drug than tremors. The results support the view that a decrease in GABA transmission plays a role in ethanol withdrawal symptoms and suggest that progabide may be tested as a possible treatment of ethanol withdrawal syndrome in man.
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
December 1976,
Science (New York, N.Y.),
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
February 1985,
Life sciences,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
May 1983,
Life sciences,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
April 1980,
The Journal of pharmacology and experimental therapeutics,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
April 1976,
Experientia,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
May 1977,
Life sciences,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
March 1999,
Pharmacology, biochemistry, and behavior,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
January 1995,
Pharmacological research,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
January 1977,
Advances in experimental medicine and biology,
F Fadda, and
E Mosca, and
R Meloni, and
G L Gessa
January 2000,
Behavioural brain research,
